MEN1611
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for MEN1611, covering 2025-05-01 to 2026-03-10. Get the full timeline:
Most recent: Clinical Trial Update: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin [Phase 2]